Artivion (NYSE:AORT) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Key Points

• Needham & Company LLC has increased its target price for Artivion (NYSE:AORT) from $45.00 to $50.00, indicating a potential upside of 15.97% from the stock's previous close.
• Artivion recently reported an earnings per share of $0.24 for the quarter, significantly beating the consensus estimate of $0.11, with a revenue of $112.97 million.
• Institutional ownership of Artivion stands at 86.37%, with notable recent investments from firms like Public Sector Pension Investment Board and Canada Life Assurance Co.

Artivion (NYSE:AORT - Get Free Report) had its price objective boosted by equities research analysts at Needham & Company LLC from $45.00 to $50.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Needham & Company LLC's price target indicates a potential upside of 14.86% from the company's current price.

A number of other research analysts have also weighed in on AORT. Oppenheimer reissued an "outperform" rating on shares of Artivion in a research report on Friday, August 8th. Stifel Nicolaus boosted their target price on shares of Artivion from $36.00 to $40.00 and gave the stock a "buy" rating in a research report on Friday, August 8th. Citizens Jmp raised shares of Artivion to a "strong-buy" rating in a research report on Tuesday, May 6th. LADENBURG THALM/SH SH lowered shares of Artivion from a "buy" rating to a "neutral" rating and boosted their target price for the stock from $32.00 to $38.80 in a research report on Wednesday, August 13th. Finally, JMP Securities boosted their target price on shares of Artivion from $33.00 to $42.00 and gave the stock a "market outperform" rating in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $40.63.

Artivion Stock Down 2.9%

Shares of AORT stock traded down $1.30 on Friday, hitting $43.53. The company's stock had a trading volume of 410,754 shares, compared to its average volume of 446,102. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48. Artivion has a fifty-two week low of $21.97 and a fifty-two week high of $45.07. The firm's fifty day moving average price is $33.65 and its 200-day moving average price is $28.83. The stock has a market capitalization of $2.05 billion, a price-to-earnings ratio of -103.64 and a beta of 1.64.

Artivion (NYSE:AORT - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.13. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The business had revenue of $112.97 million during the quarter, compared to analyst estimates of $107.96 million. The business's revenue was up 15.3% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. Research analysts anticipate that Artivion will post 0.37 EPS for the current year.

Insider Activity

In other Artivion news, insider John E. Davis sold 10,802 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $43.67, for a total transaction of $471,723.34. Following the sale, the insider directly owned 208,778 shares of the company's stock, valued at approximately $9,117,335.26. This represents a 4.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Marshall S. Stanton sold 15,000 shares of the company's stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $29.50, for a total transaction of $442,500.00. Following the transaction, the senior vice president owned 64,200 shares in the company, valued at $1,893,900. The trade was a 18.94% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 96,538 shares of company stock valued at $3,444,651 over the last three months. 8.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Artivion

Large investors have recently bought and sold shares of the business. Legacy Advisors LLC acquired a new position in Artivion in the first quarter valued at approximately $28,000. MCF Advisors LLC raised its holdings in Artivion by 109.3% in the first quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock worth $29,000 after purchasing an additional 614 shares during the period. Smartleaf Asset Management LLC raised its holdings in Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock worth $52,000 after purchasing an additional 538 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Artivion in the fourth quarter worth $64,000. Finally, Tower Research Capital LLC TRC raised its holdings in Artivion by 447.6% in the second quarter. Tower Research Capital LLC TRC now owns 5,410 shares of the company's stock worth $168,000 after purchasing an additional 4,422 shares during the period. 86.37% of the stock is currently owned by institutional investors and hedge funds.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.